Clinical trials: Chronic Hepatitis, B Virus
Hepatitis B, Chronic
Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B
Cirrhosis or cancer of the liver caused by hepatitis B virus (HBV) are major global health problems. Chronic HBV infection has become more common in Sweden with immigration.
- Trial name
- STOP-B (NCT05328427)
- Testing
- Stopping
- Where
- Sweden
- Volunteers
- 33 people
- Sponsor
- Göteborg University
Chronic Hepatitis B
Treatment Prioritisation and Cost-Effectiveness Analysis for HBV Cure - Real-World Evidence from a Territory-Wide Cohort
A number of hepatitis B virus (HBV) cure regimens including antisense oligonucleotide (ASO) and small interfering RNA (siRNA) are under vigorous clinical development and the efficacy and safety will soon be available for…
- Trial name
- NCT06627608
- Volunteers
- 10,000 people
- Sponsor
- Chinese University of Hong Kong
Hepatitis B Virus-Related Hepatocellular Carcinoma
The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy
Hepatitis B virus (HBV) infection is a global health problem, especially in the endemic area like Taiwan, where there are more than 3 million chronic hepatitis B carriers.
- Trial name
- CTEAM (NCT01957618)
- Where
- Taiwan
- Volunteers
- 1,500 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B, Chronic
TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction
Immune-tolerant patients with chronic hepatitis B (CHB) awaiting assisted reproduction (AR) are required to initiate antiviral therapy due to laboratory safety.
- Trial name
- NCT02338674
- Testing
- Tenofovir and telbivudine, Tenofovir
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Fuzhou General Hospital
Chronic Hepatitis B
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics…
- Trial name
- NCT05763576
- Testing
- RO7565020, Nucleos(t)ide analogue (NUC) treatment
- Where
- 9 sites in United States, Hong Kong and 5 more
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic Hepatitis B Virus (HBV) Infection
This study was designed for changes in endotoxaemia, endotoxin-binding factors, sICAM-1 (soluble intracellular adhesion molecule-1), and cytokines during progression of chronic HBV infection.
- Trial name
- OCEHBV (NCT01107483)
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Chronic Hepatitis B
Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B
- Trial name
- NCT07709520
- Testing
- GST-HG141, GST-HG131
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
Chronic Hepatitis b
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy(Long-term follow-up).
- Trial name
- NCT05760703
- Testing
- STSG-0002 Injection
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Chronic Hepatitis B
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
This study evaluates whether addition of Peginterferon alfa-2a to CHB Patients Treated with nucleoside analogues (NAs) can enhance the rate of HBsAg clearance at end of treatment.
- Trial name
- NCT02894918
- Testing
- Peginterferon alfa-2a
- Where
- 5 sites in China
- Volunteers
- 114 people
- Sponsor
- Henan Provincial People's Hospital
Hepatitis B
Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group
The purpose of this study is to evaluate the safety and antiviral activity of clevudine 30 mg QD for treatment of longer period (24 weeks) in patients chronically infected with HBV.
- Trial name
- NCT00313261
- Testing
- Clevudine
- Where
- 7 sites in South Korea
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis b
Study on Effect of Intestinal Microbiota Transplantation in Chronic Hepatitis B
Chronic hepatitis B(CHB) is a common infectious disease affecting up to 2 billion people worldwide. Around 650 thousand people died of liver failure, cirrhosis and primary liver cancer caused by chronic hepatitis B every year.
- Trial name
- CHB (NCT03429439)
- Testing
- intestinal microbiota transplant, Antiviral Agents
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhongshan Hospital Xiamen University
Chronic Hepatitis B
A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients
This study is SAD(Single Ascending Dose)/MAD(Multiple Ascending Dose) study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin) in Chronic Hepatitis B…
- Trial name
- NCT02569372
- Testing
- GC1102
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Green Cross Corporation
Chronic Hepatitis, Liver Cirrhosis
Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma
Adult patients with chronic hepatitis B and cirrhosis of any etiology who are found to have suspected liver cancer are potentially eligible for the study.
- Trial name
- NCT03892681
- Testing
- hepatocyte-specific contrast agent, extracellular contrast agent
- Where
- South Korea
- Volunteers
- 129 people
- Sponsor
- Yonsei University
Liver Cirrhosis, Chronic Hepatitis B
Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation
An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation.
- Trial name
- LT (NCT02125071)
- Testing
- Blood Sample Collection
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Dong-Gu Kim
Hepatitis; Virus, Chronic, Type B
A Clinical Trials to Evaluate the Efficacy and Safety of Tenofovir With and Without DWPUR001 in Patients With HBV
The patient who meets the inclusion/exclusion criteria is assigned to Test1 group or Test 2 group or control group randomly. All subjects take one pill of Viread® Tab.
- Trial name
- NCT02966964
- Testing
- DWPUR001
- Where
- 6 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Uijeongbu St. Mary Hospital
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with chronic genotype 1 or 2 HCV infection who are…
- Trial name
- NCT02613871
- Testing
- LDV/SOF
- Where
- 8 sites in Taiwan
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
PEG-IFN in HBV Patients With Incomplete Response to NA
Treatment with a nucleoside analogue and subsequent viral decline has shown to partially restore immune hyporesponsiveness in chronic hepatitis B patients.
- Trial name
- PADD (NCT00883844)
- Testing
- Nucleos(t)ide analogue treatment with a peginterferon add-on strategy, Nucleos(t)ide analogue treatment
- Where
- 2 sites in Netherlands
- Volunteers
- 11 people
- Sponsor
- Foundation for Liver Research
Liver Fibrosis
Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal…
- Trial name
- NCT07394309
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatitis B
First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
This is an open-label study to determine the safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV vaccines, with or without nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral…
- Trial name
- NCT04778904
- Testing
- ChAdOx1-HBV, MVA-HBV, Nivolumab
- Where
- 12 sites in South Korea, Taiwan and 1 more
- Volunteers
- 55 people
- Sponsor
- Barinthus Biotherapeutics
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
This study will evaluate the efficacy, safety, and tolerability of PEGASYS in participants with HBeAg-negative chronic HBV. The anticipated time on study treatment is 48 weeks, and the target sample size is 60 individuals.
- Trial name
- NCT02570191
- Testing
- Peginterferon alfa-2a
- Where
- 8 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.